Sirtex profits up eightfold

By Tim Dean
Friday, 28 August, 2009

Medical device company, Sirtex, best known for its anti-cancer SIR-Spheres, has announced an impressive boost in revenues of 72 per cent over the past financial year.

In an ASX announcement, the company has indicated a 42 per cent increase in sales of its flagship product, leading to a net profit before tax of $23 million, up from $2.5 million the previous financial year.

SIR-Spheres experienced growth in all markets, up 28 per cent in the US, 117 per cent in Europe and 17 per cent in Asia Pacific.

In today's trading, Sirtex (ASX:SRX) was up 7.7% to $4.64.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd